place

Dendreon

1992 establishments in California2000 initial public offerings2015 mergers and acquisitions2017 mergers and acquisitionsAmerican subsidiaries of foreign companies
Biotechnology companies established in 1992Biotechnology companies of the United StatesCompanies based in SeattleCompanies formerly listed on the NasdaqCompanies that filed for Chapter 11 bankruptcy in 2014

Dendreon is a biotechnology company. Its lead product, Provenge (known generically as sipuleucel-T), is an immunotherapy for prostate cancer. It consists of a mixture of the patient's own blood cells (autologous, with dendritic cells thought to be the most important) that have been incubated with the Dendreon PAP-GM-CSF fusion protein. Phase III clinical trial results demonstrating a survival benefit for prostate cancer patients receiving the drug were presented at the AUA meeting on April 28, 2009. After going through the approval process, Provenge was given full approval by the FDA on April 29, 2010. Dendreon's stock value fell 66% on August 4, 2011, after abandoning its forecast for its debut drug Provenge.In November 2014, Dendreon filed for Chapter 11 bankruptcy protection and shortly afterwards announced that it had reached agreements on the terms of a financial restructuring with certain bond holders.On February 20, 2015, Valeant Pharmaceuticals received approval to purchase all Dendreon assets. On January 9, 2017 Sanpower Group agrees to acquire Dendreon from Valeant for $819.9 million In June 2017, Sanpower Group, a Chinese conglomerate, purchased Dendreon from Valeant for $820 million.

Excerpt from the Wikipedia article Dendreon (License: CC BY-SA 3.0, Authors).

Dendreon
2nd Avenue, Seattle Belltown

Geographical coordinates (GPS) Address Nearby Places
placeShow on map

Wikipedia: DendreonContinue reading on Wikipedia

Geographical coordinates (GPS)

Latitude Longitude
N 47.607948 ° E -122.338547 °
placeShow on map

Address

Russell Investments Center

2nd Avenue 1301
98101 Seattle, Belltown
Washington, United States
mapOpen on Google Maps

Share experience

Nearby Places

Russell Investments Center
Russell Investments Center

Russell Investments Center is a 42-floor skyscraper in Seattle, Washington, United States. It is the ninth tallest building in Seattle at 182.18 m (597.7 ft), and on completion was the largest skyscraper to mark the downtown skyline in nearly 15 years. The skyscraper was originally named WaMu Center because it was built to become the new headquarters for Washington Mutual (WaMu), which intended to move most of its many Seattle-area workers into one tower, streamline operations, and encourage worker interaction, with a reinvention of the workplace. Major construction ended in early 2006, with minor construction continuing into the fall. Tenants from Washington Mutual began to move into the tower in March that year. On September 25, 2008, Washington Mutual failed, and its assets and accounts were sold to JPMorgan Chase by the Federal Deposit Insurance Corporation. On June 1, 2009, the building was renamed Chase Center. On September 9, 2009, the building was purchased by Northwestern Mutual of Milwaukee. Russell Investments, a Northwestern Mutual subsidiary, made the building its corporate headquarters upon relocation from Tacoma, Washington, and renamed the building the Russell Investments Center.The architect for the tower was NBBJ, which also designed nearby Two Union Square and other notable buildings in downtown Seattle. Sellen Construction was the general contractor for the project. The tower is located at 1301 Second Avenue, on the opposite corner from 1201 Third Avenue that was previously named Washington Mutual Tower. It includes the Seattle Art Museum (SAM) on the first four floors of the west half of the building, and connects to the museum's existing building on the southern portion of the block. WaMu and SAM made an agreement where the museum may expand in two-floor increments up to the 12th floor over the next 20 years as needed. The building also features a private 20,000 sq ft (1,900 m2) rooftop patio on the west half of the 17th floor for workers of the tower to take walks along the several walking paths.

Benaroya Hall
Benaroya Hall

Benaroya Hall is the home of the Seattle Symphony in Downtown Seattle, Washington, United States. It features two auditoria, the S. Mark Taper Foundation Auditorium, a 2500-seat performance venue, as well as the Illsley Ball Nordstrom Recital Hall, which seats 536. Opened in September 1998 at a cost of $120 million, Benaroya quickly became noted for its technology-infused acoustics designed by Cyril Harris, touches of luxury and prominent location in a complex thoroughly integrated into the downtown area. Benaroya occupies an entire city block in the center of the city and has helped double the Seattle Symphony's budget and number of performances. The lobby of the hall features a large contribution of glass art, such as one given the title Crystal Cascade, by world-renowned artist Dale Chihuly.Benaroya Hall is named for noted philanthropist Jack Benaroya, whose $15.8 million donation was the first and largest of many for construction of the facility.The hall was designed by LMN Architects of Seattle, and was awarded the National Honor Award from the American Institute of Architects in 2001. The structural engineer on the project was Magnusson Klemencic Associates. The building sits directly above the Great Northern Tunnel, which carries the primary rail corridor through the city, and adjacent to the Downtown Seattle Transit Tunnel, which has a station directly integrated into the building. The performance hall is insulated from the rumbles of the traffic in these tunnels and the streets outside the hall by floating on rubber pads which insulate it from the outer shell of the building. These same noise-insulation features would also serve to dampen the destructive effects of any prospective earthquakes.